(616 Kb) -

Explain the specific (toxicities) that led to these discontinuations. Compare these results to more recent ibrutinib studies .

: A major finding was that 41% of patients stopped taking ibrutinib within a median of 17 months. (616 KB)

: Interestingly, the most common reason for stopping the drug was toxicity (intolerance) rather than the leukemia getting worse (disease progression). Explain the specific (toxicities) that led to these

Provide a breakdown of the used by the researchers in this study. Which of these would be most helpful for you? : Interestingly, the most common reason for stopping

: Both groups had roughly the same time (about 85–87 months) from their initial diagnosis until they started ibrutinib treatment. Clinical Implications

: Despite the high rate of stopping, the overall survival and progression-free survival (estimated at 35 months) remained excellent. Real-World vs. Clinical Trials